Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?

Ann Oncol. 2015 Feb;26(2):255-6. doi: 10.1093/annonc/mdu520. Epub 2014 Nov 13.

Authors

J Oldenburg¹, M Cullen², T Tandstad³

Affiliations

¹ Department of Oncology, Akershus University Hospital, Norway and University of Oslo, Lørenskog, Norway jan.oldenburg@medisin.uio.no.
² Department of Medical Oncology, Queen Elizabeth Hospital, University Hospital Birmingham Foundation Trust, Birmingham, UK.
³ The Cancer Clinic, St Olavs University Hospital, Trondheim, Norway.

PMID: 25395282
DOI: 10.1093/annonc/mdu520

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / therapeutic use
Chemotherapy, Adjuvant / methods
Cisplatin / therapeutic use
Etoposide / therapeutic use
Humans
Male
Neoplasms, Germ Cell and Embryonal / drug therapy*
Risk Assessment
Testicular Neoplasms / drug therapy*

Substances

Bleomycin
Etoposide
Cisplatin

Supplementary concepts

BEP protocol
Testicular Germ Cell Tumor